Target Audience - The target audience for this conference is based upon a group that would benefit from learning more about problems of high-risk pregnancy. This would include perinatologists, general OB-GYN’s and nursing staff involved in the care of high-risk pregnancies, both within the office and within a hospital setting.

Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, Irvine College of Medicine and Nevada Perinatal Foundation. The University of California, Irvine College of Medicine is accredited by the ACCME to provide continuing medical education
for physicians.

Designation Statement:
The University of California, Irvine College of Medicine designates this educational activity for a maximum of 19 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Disclosure:
It is the policy of the University of California, Irvine College of Medicine that the faculty and sponsor discloses real or apparent conflict of interest relating to the topics of this educational activity and also discloses discussion of unlabelled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosure will be made in writing in the activity handout materials.

ADA
In compliance with the Americans’ with Disabilities Act, please notify Stephanie Aguilar at (702) 382-3200 if you have any special needs. We will make every reasonable effort to comply with your request.

Objectives
1) Define new information on dealing with preeclampsia.

2) Identify appropriate management of the patient with oligohydramnios.

3) Recognize the new role of progesterone for the prevention of prematurity.

4) Define of ultrasound modalities
and management of twin gestations, especially that of monoamniotic twin gestations.

5) Recognize etiologies and prevention of cerebral palsy in the antepartum period
and the new task force requirement on the documentation on the development of intrapartum cerebral palsy.

6) Identify and recognize the ethical usage and new treatment uses for umbilical cord stem cells.

7) Recognize more uses of information
on abnormalities via ultrasound and management, specifically of performance and management of fetal intracranial ultrasonography.

8) Recognize rational protocols for the patient with previable, preterm premature rupture of membranes.

9) Identify reasons why patients litigate against their obstetrician/gynecologist.

We wish to thank Valley Hospital Center and The Phillips Corporation for their grant in support of this activity.